/stocks — the workspaceLOADING
All INMD SEC filings, by type → · Earnings date & implied move · Search inside filings
InMode Ltd. (INMD) is a electromedical & electrotherapeutic apparatus company. Piotroski F-Score 3/8. 4 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind INMD’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Stage-1 growth down the side, discount rate across the top, with terminal growth at 2.5% and 10 years of stage 1. Every cell runs the same two-stage DCF as the card above, so moving a slider moves the grid.
| Growth ↓ Discount → | 7% | 8% | 9% | 10% | 11% |
|---|---|---|---|---|---|
| 4% | 34.22 | 27.87 | 23.49 | 20.27 | 17.82 |
| 6% | 40.22 | 32.59 | 27.32 | 23.47 | 20.53 |
| 8% | 47.26 | 38.09 | 31.78 | 27.18 | 23.67 |
| 10% | 55.49 | 44.52 | 36.98 | 31.48 | 27.31 |
| 12% | 65.09 | 52.00 | 43.01 | 36.48 | 31.53 |
| Growth the close implies | -7.1% | -4.9% | -3.0% | -1.2% | 0.5% |
Outlined: your current pair. Shaded: at or above the last close, 13.97 USD. The heavy line runs between the cells on either side of it.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from INMD’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on INMD plus an auto-SWOT — built from INMD's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate INMD using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has INMD been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as INMD tagged it: revenue us-gaap:Revenues, net income us-gaap:ProfitLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
Projected from INMD's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentINMD files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No lawmaker has disclosed a trade in INMD under the STOCK Act.
1 of 5 estimators could run on INMD's filings. A band needs at least 2.
One estimator is a point estimate, not a range, so no band and no valuation label are published for INMD. Below is everything that was checked, so the refusal can be read rather than taken on trust.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for INMD, so sector medians could not fill the gaps.
Every refusal recorded for INMD → · How often we decline, and why →
No tracked institution reported a position in INMD in the latest 13F round.
Shareholder returns exceeded free cash flow this period — the difference was funded from cash on hand, debt, or asset sales rather than the business itself. Common and sustainable for a period; worth watching if it persists.
Every figure is from INMD’s SEC cash-flow statement. This describes how management deployed cash last period — it is not a grade of that deployment, not a forecast, and not investment advice. Whether reinvesting, paying down debt, or returning cash was the right call depends on the return each earns, which the filings do not settle. Educational information only.
No open-market Form 4 buys or sells reported for INMD in the last ~6 months.
1 of the 2 checks that ran found nothing new for INMD; 1 found something. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
Head office: Yokneam, Israel
Source: the cover page of InMode Ltd.’s 20-F filed 2026-02-10, on EDGAR. Filings checked 2026-10-25. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works